Lyra Therapeutics Files 8-K with Corporate Updates
Ticker: LYRA · Form: 8-K · Filed: Jun 18, 2024 · CIK: 1327273
| Field | Detail |
|---|---|
| Company | Lyra Therapeutics, INC. (LYRA) |
| Form Type | 8-K |
| Filed Date | Jun 18, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing, financial-reporting
TL;DR
Lyra Therapeutics filed an 8-K on June 13th detailing corporate changes and financial updates.
AI Summary
Lyra Therapeutics, Inc. filed an 8-K on June 18, 2024, reporting events that occurred on June 13, 2024. The filing indicates changes to the company's articles of incorporation or bylaws, submission of matters to a vote of security holders, and financial statements and exhibits. No specific financial figures or vote outcomes were detailed in the provided text.
Why It Matters
This 8-K filing signals important corporate governance and financial reporting updates for Lyra Therapeutics, Inc., which could impact investor understanding of the company's structure and recent activities.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not contain information about significant financial distress, operational failures, or major strategic shifts that would inherently increase risk.
Key Players & Entities
- Lyra Therapeutics, Inc. (company) — Registrant
- June 13, 2024 (date) — Earliest event reported
- June 18, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific amendments were made to Lyra Therapeutics' articles of incorporation or bylaws?
The provided text of the 8-K filing does not specify the exact nature of the amendments to the articles of incorporation or bylaws.
What matters were submitted to a vote of Lyra Therapeutics' security holders?
The filing indicates that matters were submitted to a vote, but the specific details of these matters are not included in the provided text.
Are there any new financial statements or exhibits filed with this 8-K?
Yes, the filing states that 'Financial Statements and Exhibits' are being submitted, but the content of these is not detailed in the provided text.
What is the primary reason for Lyra Therapeutics filing this 8-K report?
The 8-K is filed to report significant corporate events, including amendments to governing documents, matters submitted for shareholder vote, and the filing of financial statements and exhibits, all occurring on or around June 13, 2024.
When was Lyra Therapeutics, Inc. incorporated?
Lyra Therapeutics, Inc. was incorporated in Delaware, as indicated by the filing.
Filing Stats: 900 words · 4 min read · ~3 pages · Grade level 12 · Accepted 2024-06-18 16:06:02
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share LYRA The Nasdaq
Filing Documents
- d614069d8k.htm (8-K) — 38KB
- d614069dex31.htm (EX-3.1) — 33KB
- 0001193125-24-163395.txt ( ) — 205KB
- lyra-20240613.xsd (EX-101.SCH) — 3KB
- lyra-20240613_lab.xml (EX-101.LAB) — 18KB
- lyra-20240613_pre.xml (EX-101.PRE) — 11KB
- d614069d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Restated Certificate of Incorporation of Lyra Therapeutics, Inc., dated May 5, 2020 and the Certificate of Amendment to the Restated Certificate of Incorporation of Lyra Therapeutics, Inc., dated June 13, 2024. 104 Cover Page Interactive Data File (embedded within the inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lyra Therapeutics, Inc. Date: June 18, 2024 By: /s/ Jason Cavalier Jason Cavalier Chief Financial Officer